Myeloid Therapeutics, Inc. (“Myeloid”), a clinical stage biotechnology company advancing RNA immunotherapies to conquer cancer, today announced its participation at Chardan’s 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit, taking place virtually April 29-30.
CAMBRIDGE, Mass., April 15, 2024 /PRNewswire/ -- Myeloid Therapeutics, Inc. (“Myeloid”), a clinical stage biotechnology company advancing RNA immunotherapies to conquer cancer, today announced its participation at Chardan’s 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit, taking place virtually April 29-30. Daniel Getts, Ph.D., Chief Executive Officer of Myeloid, will participate in a fireside chat on Monday, April 29, 2024, at 11:30 am ET. Company management will also participate in one-on-one meetings with investors during the event. About Myeloid Therapeutics Myeloid Therapeutics is a clinical stage immunology company, engineering cutting-edge RNA technology to program immune cells to combat cancer and other deadly diseases. Myeloid is headquartered in Cambridge, MA. For additional information, please visit, https://www.myeloidtx.com/ and follow us on LinkedIn and X/Twitter. Investor Contact
View original content to download multimedia:https://www.prnewswire.com/news-releases/myeloid-therapeutics-to-participate-in-chardans-8th-annual-genetic-medicines-and-cell-therapy-manufacturing-summit-302117236.html SOURCE Myeloid Therapeutics |